A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Clinical trial NCT04556292 · UNKNOWN

Trial details

NCT number: NCT04556292
Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Metastatic BRCA 1 Gene Mutation BRCA 2 Gene Mutation

Start date: 2020-08-12
Primary completion: 2022-03-30
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.